Julie D. Constable
Julie D. Constable represents public and private companies in the pharmaceutical, biotechnology, medical device and health care industries at all stages of development. Julie regularly advises her clients in a variety of transactions, including public and private securities offerings, mergers and acquisitions, license and collaboration agreements, securities law compliance and general corporate matters.
Prior to joining Ropes & Gray, Julie worked in the health care industry specializing in policy matters related to access, cost containment, quality and safety. Additionally, she published articles in a variety of news organizations, including The Boston Globe, The New York Times and CNN.com. Julie holds a M.S. in Health Policy and Management from the Harvard School of Public Health.
- Served as in-house corporate counsel on six-month secondment to Waters Corporation, advising on strategic partnerships, including negotiating technology licensing arrangements and manufacturing, supply and distribution agreements with business partners.
- Represented Mersana Therapeutics in its licensing agreement with Synaffix B.V., in which Mersana obtained worldwide rights, on a target-by-target basis, to Synaffix B.V.’s GlycoConnect™ antibody drug conjugate technology.
- Represented Waters Corporation in its acquisition of Desorption Electrospray Ionization (DESI) technology assets from Prosolia, Inc.
- Represented Mersana Therapeutics in its $75 million initial public offering.
- Represented Lilly Asia Ventures in its investments in Gritstone Oncology, Inc. in its $92.7 million Series B round and E-Scape Bio in its $63 million Series A round.
- Represented Kastle Therapeutics in its acquisition of global rights to develop and commercialize KYNAMRO® from Ionis Pharmaceuticals for consideration totaling up to $95 million.
- Represented Aegerion Pharmaceuticals, Inc. in its acquisition of the commercial drug Myalept from AstraZeneca for a $325 million upfront payment.
- Represented Cubist Pharmaceuticals, Inc. in its $818 million acquisition of Trius Therapeutics, Inc.
- Represented Genocea Biosciences, Inc. in its $66 million initial public offering and $51.7 million follow-on public offering.
- Represented TPG Biotech and Longitude Venture Partners in a $31.5 million series B preferred stock financing of Rapid Micro Biosystems.
- Represented Becton Dickinson on the divestiture of BD Rx Inc. to Fresenius Kabi USA, Inc.
- David M. McIntosh, James S. DeGraw, Nathaniel K. Kurtis and Julie D. Polovina, "Meso Scale V. Roche Rethinks Reverse Triangular Mergers," Law360 (March 21, 2013)
- Julie D. Polovina, “Mutant Biologics: The 2010 Health-Reform Legislation’s Potential Impact on Reducing Biologic Research and Development Costs,” 100 Georgetown Law Review 2291, 2291-324 (2012)